412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors - Garralda, Elena; Geva, Ravit; Ben-Ami, Eytan; Maurice-Dror, Corinne; Calvo, Emiliano; LoRusso, Patricia; Türeci, Özlem; Niewood, Michelle; Şahin, Uğur; Jure-Kunkel, Maria; Forssmann, Ulf; Ahmadi, Tahamtan; et al. (Journal for immunotherapy of cancer, 2020)
Keywords: Breast cancer; Cancer therapies; Consent; Immune checkpoint inhibitors; Immunomodulators; Immunotherapy; Ovarian cancer; Tumors